The Chemours Company (NYSE:CC) Shares Sold by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans reduced its position in shares of The Chemours Company (NYSE:CC) by 0.4% during the third quarter, Holdings Channel.com reports. The fund owned 244,587 shares of the specialty chemicals company’s stock after selling 1,001 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Chemours were worth $4,970,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. New Covenant Trust Company N.A. acquired a new stake in shares of Chemours during the 1st quarter valued at $29,000. Blue Trust Inc. raised its position in shares of Chemours by 166.9% during the third quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 731 shares during the period. Matrix Trust Co purchased a new stake in shares of Chemours during the third quarter valued at $25,000. Signaturefd LLC boosted its position in shares of Chemours by 163.7% in the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company’s stock valued at $40,000 after purchasing an additional 1,216 shares during the period. Finally, Itau Unibanco Holding S.A. acquired a new position in shares of Chemours in the 2nd quarter valued at $58,000. 76.26% of the stock is currently owned by institutional investors.

Chemours Stock Up 3.5 %

CC stock opened at $21.53 on Friday. The company has a 50 day moving average of $19.39 and a two-hundred day moving average of $21.53. The company has a market cap of $3.22 billion, a price-to-earnings ratio of 43.06 and a beta of 1.75. The Chemours Company has a 12-month low of $15.10 and a 12-month high of $32.70. The company has a quick ratio of 0.92, a current ratio of 1.73 and a debt-to-equity ratio of 6.05.

Chemours (NYSE:CC) last announced its quarterly earnings data on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.08. Chemours had a return on equity of 29.48% and a net margin of 1.34%. The business had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.44 billion. During the same period last year, the company earned $0.64 earnings per share. Chemours’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities analysts anticipate that The Chemours Company will post 1.35 earnings per share for the current fiscal year.

Chemours Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 16th. Stockholders of record on Friday, November 15th will be issued a dividend of $0.25 per share. The ex-dividend date is Friday, November 15th. This represents a $1.00 annualized dividend and a dividend yield of 4.64%. Chemours’s dividend payout ratio is 200.00%.

Wall Street Analysts Forecast Growth

CC has been the subject of a number of analyst reports. UBS Group reduced their price objective on shares of Chemours from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. The Goldman Sachs Group cut their price target on shares of Chemours from $29.00 to $23.00 and set a “neutral” rating on the stock in a report on Tuesday, September 3rd. Royal Bank of Canada lowered their price objective on shares of Chemours from $28.00 to $25.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 6th. BMO Capital Markets boosted their target price on shares of Chemours from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, October 7th. Finally, JPMorgan Chase & Co. decreased their target price on Chemours from $25.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $24.88.

Insider Activity at Chemours

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $20.64, for a total transaction of $154,800.00. Following the transaction, the senior vice president now directly owns 16,645 shares of the company’s stock, valued at $343,552.80. This represents a 31.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.47% of the stock is currently owned by company insiders.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.